523 6. Complicanze tardive Bibliografia 1. Ahya, V.N. Noninfectious Acute Lung Injury Syndromes Early After Hematopoietic Stem Cell Transplantation. Clin Chest Med 2017, 38, 595–606, doi:10.1016/j.ccm.2017.07.002. 2. DynaMed Pulmonary Complications of Hematopoietic Stem Cell Transplant (Allogeneic and Autologous). 3. Bergeron, A.; Cheng, G.-S. Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. Clin Chest Med 2017, 38, 607–621, doi:10.1016/j.ccm.2017.07.003. 4. Diab, M.; ZazaDitYafawi, J.; Soubani, A.O. Major Pulmonary Complications After Hematopoietic Stem Cell Transplant. Exp Clin Transplant 2016, 14, 259–270, doi:10.6002/ect.2015.0275. 5. Sorror, M.L.; Maris, M.B.; Storb, R.; Baron, F.; Sandmaier, B.M.; Maloney, D.G.; Storer, B. Hematopoietic Cell Transplantation (HCT)-Specific Comorbidity Index: A New Tool for Risk Assessment before Allogeneic HCT. Blood 2005, 106, 2912–2919, doi:10.1182/blood-2005-05-2004. 6. Carreras E, Cooke KR. Noninfectious Pulmonary Complications. In The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]; Springer: Cham (CH), 2019; p. Table 52.4 ISBN doi: 10.1007/978-3-030-02278-5_52. 7. Gazourian, L.; Rogers, A.J.; Ibanga, R.; Weinhouse, G.L.; Pinto-Plata, V.; Ritz, J.; Soiffer, R.J.; Antin, J.H.; Washko, G.R.; Baron, R.M.; et al. Factors Associated with Bronchiolitis Obliterans Syndrome and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Am J Hematol 2014, 89, 404–409, doi:10.1002/ajh.23656. 8. Bergeron, A.; Chevret, S.; Peffault de Latour, R.; Chagnon, K.; de Margerie-Mellon, C.; Riviere, F.; Robin, M.; Mani, J.; Lorillon, G.; Socie, G.; et al. Noninfectious Lung Complications after Allogeneic Haematopoietic Stem Cell Transplantation. Eur Respir J 2018, 51, 1702617, doi:10.1183/13993003.02617-2017. 9. Bondeelle, L.; Bergeron, A. Managing Pulmonary Complications in Allogeneic Hematopoietic Stem Cell Transplantation. Expert Rev Respir Med 2019, 13, 105–119, doi:10.1080/17476348. 2019.1557049. 10. Dignan, F.L.; Scarisbrick, J.J.; Cornish, J.; Clark, A.; Amrolia, P.; Jackson, G.; Mahendra, P.; Taylor, P.C.; Shah, P.; Lightman, S.; et al. Organ-Specific Management and Supportive Care in Chronic Graft-versus- Host Disease. Br J Haematol 2012, 158, 62–78, doi:10.1111/j.1365a-2141.2012.09131.x. 11. Jagasia, M.H.; Greinix, H.T.; Arora, M.; Williams, K.M.; Wolff, D.; Cowen, E.W.; Palmer, J.; Weisdorf, D.; Treister, N.S.; Cheng, G.-S.; et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2015, 21, 389-401.e1, doi:10.1016/j. bbmt.2014.12.001. 12. Carpenter, P.A.; Kitko, C.L.; Elad, S.; Flowers, M.E.D.; Gea-Banacloche, J.C.; Halter, J.P.; Hoodin, F.; Johnston, L.; Lawitschka, A.; McDonald, G.B.; et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2015, 21, 1167–1187, doi:10.1016/j.bbmt.2015.03.024. 13. Bergeron, A.; Chevret, S.; Granata, A.; Chevallier, P.; Vincent, L.; Huynh, A.; Tabrizi, R.; Labussiere-Wallet, H.; Bernard, M.; Chantepie, S.; et al. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. JAMA 2017, 318, 557–566, doi:10.1001/jama.2017.9938. 14. Nakasone, H.; Onizuka, M.; Suzuki, N.; Fujii, N.; Taniguchi, S.; Kakihana, K.; Ogawa, H.; Miyamura, K.; Eto, T.; Sakamaki, H.; et al. Pre-Transplant Risk Factors for Cryptogenic Organizing Pneumonia/Bronchiolitis Obliterans Organizing Pneumonia after Hematopoietic Cell Transplantation. Bone Marrow Transplant 2013, 48, 1317–1323, doi:10.1038/bmt.2013.116.
RkJQdWJsaXNoZXIy ODUzNzk5